Incidence, Mortality and Characteristics of Patients Admitted With Pulmonary Alveolar Proteinosis in the United States

Tome, Rodrigo García; McElyea, Christine; Chang, Chenbei

doi:10.1016/j.chest.2020.08.969

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Increased costs were attributed to disease-related treatments, including prescriptions, hospitalizations, and outpatient visits. In another retrospective cohort study of 500 U.S. patients admitted with a primary diagnosis of PAP between 2012 and 2014, mean actual cost per admission was $29,932 (CI: 13,739-46,124) with an overall annual cost burden of approximately $5 million ( 130 ).…”

Section: Autoimmune Pulmonary Alveolar Proteinosis (Apap): a Gm-csf D...mentioning

confidence: 99%

Recombinant GM-CSF for diseases of GM-CSF insufficiency: Correcting dysfunctional mononuclear phagocyte disorders

Lazarus

Pitts²,

Wang

et al. 2023

Front. Immunol.

View full text Add to dashboard Cite

IntroductionEndogenous granulocyte-macrophage colony-stimulating factor (GM-CSF), identified by its ability to support differentiation of hematopoietic cells into several types of myeloid cells, is now known to support maturation and maintain the metabolic capacity of mononuclear phagocytes including monocytes, macrophages, and dendritic cells. These cells sense and attack potential pathogens, present antigens to adaptive immune cells, and recruit other immune cells. Recombinant human (rhu) GM-CSF (e.g., sargramostim [glycosylated, yeast-derived rhu GM-CSF]) has immune modulating properties and can restore the normal function of mononuclear phagocytes rendered dysfunctional by deficient or insufficient endogenous GM-CSF.MethodsWe reviewed the emerging biologic and cellular effects of GM-CSF. Experts in clinical disease areas caused by deficient or insufficient endogenous GM-CSF examined the role of GM-CSF in mononuclear phagocyte disorders including autoimmune pulmonary alveolar proteinosis (aPAP), diverse infections (including COVID-19), wound healing, and anti-cancer immune checkpoint inhibitor therapy.ResultsWe discuss emerging data for GM-CSF biology including the positive effects on mitochondrial function and cell metabolism, augmentation of phagocytosis and efferocytosis, and immune cell modulation. We further address how giving exogenous rhu GM-CSF may control or treat mononuclear phagocyte dysfunction disorders caused or exacerbated by GM-CSF deficiency or insufficiency. We discuss how rhu GM-CSF may augment the anti-cancer effects of immune checkpoint inhibitor immunotherapy as well as ameliorate immune-related adverse events.DiscussionWe identify research gaps, opportunities, and the concept that rhu GM-CSF, by supporting and restoring the metabolic capacity and function of mononuclear phagocytes, can have significant therapeutic effects. rhu GM-CSF (e.g., sargramostim) might ameliorate multiple diseases of GM-CSF deficiency or insufficiency and address a high unmet medical need.

show abstract

Section: Autoimmune Pulmonary Alveolar Proteinosis (Apap): a Gm-csf D...mentioning

confidence: 99%

Recombinant GM-CSF for diseases of GM-CSF insufficiency: Correcting dysfunctional mononuclear phagocyte disorders

Lazarus

Pitts²,

Wang

et al. 2023

Front. Immunol.

View full text Add to dashboard Cite

show abstract

Incidence, Mortality and Characteristics of Patients Admitted With Pulmonary Alveolar Proteinosis in the United States

Cited by 1 publication

References 0 publications

Recombinant GM-CSF for diseases of GM-CSF insufficiency: Correcting dysfunctional mononuclear phagocyte disorders

Recombinant GM-CSF for diseases of GM-CSF insufficiency: Correcting dysfunctional mononuclear phagocyte disorders

Contact Info

Product

Resources

About